stress are associated with increased AGEs levels. Indeed, increased serum and skin AGEs are found in patients with diabetes mellitus compared to controls. [11] [12] [13] Oxidative stress plays a role in the pathogenesis of both AAA and PAD. 14, 15 In line with this reasoning, increased serum AGEs and skin AGEs were found in patients with PAD as compared to controls. 16, 17 Furthermore, our data show increased skin AGEs, noninvasively assessed, in 252 AAA patients compared to controls (Boersema J et al., unpublished data, 2016). Two effects of
AGEs have been described, namely formation of cross-links on long-lived proteins, and induction of cellular stress responses by engagement of the receptor for AGEs (RAGE). 18 Cross-linking causes stiffness, but may also protect against mechanical structure loss of the affected tissues. The association between AGEs and arterial stiffness is shown in several studies. In patients with end stage renal disease as well as in type 1 diabetes mellitus, skin
AGEs level was associated with pulse wave velocity, a measure of arterial stiffness. 19, 20 Increased arterial stiffness is associated with atherosclerotic disease. 21 However, in a mouse model homogenous stiffening reduced aneurysm growth, while segmental aortic stiffening caused aneurysm growth. 22 Therefore, the aim of the ARTERY study (Advanced glycation end pRoducts in patients with peripheral arTery disEase and abdominal aoRtic aneurYsm study) is to identify the association between the presence of diabetes mellitus and increased accumulation of AGEs and arterial stiffening in the vascular wall in AAA and in PAD patients. If an association would be found, it would support our hypothesis that increased AGE accumulation may cause homogenous stiffness of the vascular wall and protects against AAA development and growth, but increases atherosclerosis in PAD. 
METHODS

Objectives
Primary objectives
To compare the amount of AGEs in the vascular wall between patients with and without diabetes mellitus suffering from:
-Abdominal aortic aneurysm.
-Peripheral artery disease.
Secondary objectives
Our secondary objectives are:
-To compare types and location of the AGEs between patients with and without diabetes mellitus.
-To evaluate the relation between the amount of AGEs and vascular stiffness within all subgroups.
-To correlate AGEs in the vascular wall to serum, urine and skin AGEs in the whole study group.
Study design
The ARTERY study is designed as a cross-sectional multi-center study, performed in three centers in The Netherlands.
Participants
Patients from at least 18 years on, willing to participate are eligible for the study. Patients will be included in case of the diagnosis AAA or PAD in whom an indication for open surgery exists. Patients with concomitant AAA and PAD will be excluded as well as patients with inflammatory disorders will be excluded. Detailed inclusion and exclusion criteria are shown in Table 1 . Patients will be divided into four groups, based on the diagnosis AAA or PAD and presence or absence of diabetes mellitus. American Diabetes Association guidelines will be used to define diabetes mellitus. The diagnosis diabetes mellitus will be supposed by a random glucose ≥ 11.1 mmol/L, HbA1c ≥ 6.5% or 48 mmol/mol, or a history of diabetes mellitus. 1 In total, 120 patients will be included in the ARTERY study. This number is based on two sample size calculations. For our primary objective, calculation was based on a study which compared the content of the specific AGE pentosidine in plaques of diabetic and nondiabetic patients with carotid artery stenosis. In this study, a significant difference was found in 7 patients with diabetes mellitus (197.0 ± 34.0 pmol/mg collagen) and 20 patients without diabetes mellitus (111.9 ± 16.2 pmol/mg collagen). 23 With a power of 80% and an alpha of 5%, each group has to consist of 3 patients. With four groups in our study this would result in at least 12 patients. However, for our secondary objectives, an additional sample size calculation was performed. This calculation was based on skin AGEs in patients with and without diabetes mellitus. This study reported a mean skin AGE level of 2.79 ± 0.8 arbitrary units (AU) in 973 patients with diabetes mellitus and 2.14 ± 0.6 AU in 231 patients without diabetes mellitus. 13 To show a similar difference between patients with and without diabetes mellitus of skin AGEs, 25 patients per group are required. Taking a failure plus dropout rate of 20% into account together with the possibility of subgroup analysis, we should include 30 patients per subgroup, and a total of 120 patients. have an appointment in the vascular laboratory. Blood will be drawn and 24-hour urine will be collected before surgery. Several biopsies will be obtained during surgery, depending on the type of surgery, and of which more details are shown below. Collected tissue biopsies will be stored until analysis.
Blood and urine sampling
Blood will be sampled for routine analysis and stored to determine AGEs. For direct analysis blood will be drawn in an EDTA tube, lithium-heparin tube and a sodium fluoride tube. Citrate plasma, EDTA plasma and serum will be stored at -80° Celsius. For the analysis of AGEs, EDTA tubes will be used for blood collection, which will be transported on ice, centrifuged on 4° Celsius and stored at -80° Celsius until batch analysis.
Patients will be asked to collect urine for 24 hours and to keep the container cool until the urine is returned to the laboratory. The urine will be centrifuged, routine analysis will be performed and samples will be stored at -80° Celsius.
Biopsy
During surgery, full-thickness biopsies from the arterial wall will be taken at pre-defined locations. These biopsies will be marked with sutures to assure cranio-caudal directions.
In case of an open aneurysm repair, a biopsy will be obtained 5 centimeter below the lowest renal artery on the left ventral side with a size of 3 (length) x 1 (width)
centimeter.
In case of bypass surgery for PAD, a biopsy will be obtained from the proximal anastomosis in the groin of 1 (length) x 0.5 (width) centimeter.
-
In case of an endarterectomy for PAD, usually the common femoral artery, a biopsy will be obtained from the proximal part of the artery with a size of 1 (length) x 0.5 (width) centimeter.
Page 8 of 22
For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9 In addition, skin tissue, venous tissue and fat tissue will be obtained and stored as described below. Skin tissue will be obtained from the incision with a width of 1 (length) x 0.5 (width) x 1 (depth) centimeter. Venous tissue is only available in case of an autologous venous bypass. In that case, a circular segment from the venous graft will be obtained at the level of the distal anastomosis with a size of 0.25-0.50 centimeter. Peri-aortic adipose tissue will be obtained during open aneurysm repair.
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Storage
After surgery, biopsy material of the arterial tissue will be divided into three equal parts. The first two parts, together with skin, venous and adipose tissue, will be snap frozen and stored at -80° Celsius. The third part, marked with a suture on the most distal part of the biopsy, will be stored in formaldehyde for 24-72 hours. Afterwards, tissue will be dehydrated with ethanol and embedded in paraffin. Materials of MST will be fixed with formaldehyde, stored in 96% ethanol, and transported to the UMCG per batch of 10 samples where these tissues will be embedded in paraffin. Table 2 shows an overview of the outcome measures and measurement methods, which will be described in detail in the following paragraphs.
Outcome measures
Demographics
The patients' characteristics such as date of birth, sex, cardiovascular risk factors, cardiovascular disease, cardiovascular family history and drug use will be assessed by evaluating medical records and will be confirmed or complemented by a questionnaire consisting of 25 questions.
Weight and length will be recorded during visit at the vascular laboratory. Routine blood and urine analysis will be performed to evaluate the presence of diabetes mellitus and to determine several cardiovascular risk factors, including renal function.
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AGEs in fluids
Specific protein-bound plasma and urine AGEs, CML, CEL and MG-H1, will be measured with UPLC-MS/MS, as described previously. 25 Protein-bound plasma and urine pentosidine will be measured using high performance liquid chromatography (HPLC), as described previously.
26
Skin AGEs
AGEs in the skin will be assessed non-invasively with the AGE Reader TM (DiagnOptics Technologies BV, Groningen, The Netherlands). This method uses ultraviolet light to excite specific AGEs. Reflection and emission light are detected and converted into a skin autofluorescence level expressed in arbitrary units. Detailed information about this method is described elsewhere. 27 Both inner forearms will be scanned three times. Patients will be asked not to use sun blockers, skin tanners or skin creams two weeks before the measurement, since these creams influence the skin autofluorescence measurement. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   11   Vascular parameters Several vascular parameters will be obtained for the ARTERY study. These parameters include blood pressures, toe pressures, and duplex ultrasound of the aorta. In addition, carotid artery intima-media thickness and carotid-femoral pulse wave velocity will be measured in the vascular laboratory of the UMCG only. Measurements will be performed by trained vascular technicians.
Brachial artery blood pressures will be measured three times on both arms in sitting position after 10 minutes of rest.
For the ankle-brachial index measurement, patients should be in supine position.
For the ankle-brachial index, the systolic pressure will be measured of the brachial artery, and both the posterior tibial artery and the dorsalis pedis artery bilaterally. This will be measured during cuff release using a Doppler probe. Toe-brachial index will be measured using toe photo-electric plethysmography during gradual pressure release of a cuff placed at the base of the first toe, the toe pressure being defined by reappearance of the plethysmographic signal.
Screening to exclude concomitant AAA and PAD will be performed with duplex ultrasound in supine position. An AAA will only be reassessed in case the last imaging procedure was more than two months ago.
Carotid intima-media thickness will be measured as a marker of generalized atherosclerotic burden. The far wall of the left and right common carotid artery will be measured with the MyLabOne (Esaote Europe B.V., Maastricht, The Netherlands). Three measurements will be performed with an average of 6 heart beats of the wall segment of 10 millimeters before the transition to the carotid bulb.
For the measurement of the carotid-femoral pulse wave velocity, patients are asked not to drink coffee or alcohol and not to smoke three hours before the measurement.
Patients are allowed to have a light meal. Arterial waveforms will be obtained from the carotid and femoral artery and the time delay will be measured between the feet of the two 
Data handling and statistical analysis
Informed consent forms will be collected and stored at the UMCG. Biomaterials from patients will be coded. All generated data will be stored coded in an electronic Case Report File with the software OpenClinica. Data will be exported to SPSS software (IBM Corp. Armonk, NY, USA) for statistical analysis.
Described data will be shown as mean with standard deviation for normal distributed variables, mean with interquartile range for skewed data and number with percentages for categorical data. Difference between groups will be tested with the independent student t test or non-parametric tests for skewed data. For categorical variables, Chi-square test will be performed. A P<0.05 will be considered significant.
Ethical considerations
Ethical approval was obtained from the UMCG Medical Ethics committee (METc 2014/269).
Local approval for the ARTERY study was given by the Medical Ethics committee and the Although we designed our study carefully, there are some limitations. We do not exclude patients suffering from renal insufficiency. These patients also have increased AGEs accumulation. 37 We have chosen not to exclude these patients, since patients with vascular disease frequently have renal insufficiency. Exclusion of concurrent renal failure and vascular disease would result in a selection bias. Therefore, we have decided to increase our sample size to allow subgroup analysis. In addition, renal function will be a variable which will be included into multivariate analyses. In addition, biopsy material obtained at the location of disease may not be representative for vascular tissue in general. We standardize the biopsies procedure to minimize location specific differences. However, it is technically and ethically not possible to obtain additional biopsies from different vascular sites to determine whether AGEs are distributed equally.
In conclusion, the ARTERY study will investigate the diverging effects of diabetes mellitus on AAA and PAD and the role of AGEs as possible explanatory factor. The study will be conducted in a multicenter setting. Primary objective is to analyze AGEs in the arterial wall. As secondary objectives, AGEs of the arterial wall will be compared to AGE measurements in blood, urine and skin, and with vascular wall parameters.
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Methods and analysis:
This cross-sectional multicenter study will compare the amount, type and location of AGEs in the arterial wall in a total of 120 patients with AAA or PAD with and without diabetes mellitus (n=30 per subgroup). Also, local and systemic vascular parameters, including pulse wave velocity, will be measured to evaluate the association between arterial stiffness and AGEs. Finally, AGEs will be measured in serum, urine and assessed in skin with skin autofluorescence using the AGE Reader TM .
Ethics and dissemination: This study is approved by the Medical Ethics committees of University Medical Center Groningen, Martini Hospital and Medisch Spectrum Twente, The
Netherlands. Study results will be disseminated through peer-reviewed journals and scientific events.
Trial registration: trialregister.nl NTR 5363.
Strengths and limitation of this study
+ Large number of arterial tissue samples (n=120). 3 In addition, AAA growth was shown to be decreased substantially in patients with diabetes mellitus (n=49) as compared to patients without diabetes mellitus (n=311) after 36 months of follow-up. 4 The explanation for the diverging effects of diabetes mellitus on occlusive versus dilating arterial disease remains unclear.
Differences in effects of diabetes mellitus on aorta versus large peripheral arteries may contribute to these diverging effects. 5, 6 AAA is characterized by inflammation of the tunica media with matrix metalloproteinase and macrophage activation, causing proteolysis and smooth muscle cell apoptosis. 7, 8 In contrast, PAD results from inflammation of the tunica intima and increased endothelial permeability, macrophage infiltration, retention of cholesterol and recruitment of smooth muscle cells which form a fibrous cap. 9 Nevertheless,
AAA and PAD appears often simultaneously in patients, possibly due to their common risk factors. Diabetes-induced changes in arterial pulse wave propagation and reflection may be another factor contributing to the diverging effects of diabetes on increased occlusive arterial disease in the lower extremities, and relative protection against AAAs. Type 2 diabetes is associated with increased aortic stiffness, without abnormalities in aortic diameter or carotid stiffness. 10 Subjects with type 2 diabetes demonstrate a decreased reflection magnitude, which may indicate an increased penetration of pulsatile energy to distal vascular beds. 10 Advanced glycation end products (AGEs) might also play a role in these different effects of diabetes mellitus on vascular tissues. AGEs are formed by non-enzymatic Cross-linking causes stiffness, but may also protect against mechanical structure loss of the affected tissues. The association between AGEs and arterial stiffness is shown in several studies. In patients with end stage renal disease as well as in type 1 diabetes mellitus, skin
AGEs level was associated with pulse wave velocity, a measure of arterial stiffness. 19, 20 Increased arterial stiffness is associated with atherosclerotic disease. 21 However, in a mouse model homogenous stiffening reduced aneurysm growth, while segmental aortic stiffening caused aneurysm growth. 
METHODS
Objectives
Primary objectives
Secondary objectives
Study design
Participants
Patients from at least 18 years on, willing to participate are eligible for the study. Patients will be included in case of the diagnosis AAA or PAD in whom an indication for open surgery exists. Patients with concomitant AAA and PAD will be excluded as well as patients with inflammatory disorders. Detailed inclusion and exclusion criteria are shown in Table 1 .
Patients will be divided into four groups, based on the diagnosis AAA or PAD and presence In total, 120 patients will be included in the ARTERY study. This number is based on two sample size calculations. For our primary objective, calculation was based on a study which compared the content of the specific AGE pentosidine in plaques of diabetic and nondiabetic patients with carotid artery stenosis. In this study, a significant difference was found in 7 patients with diabetes mellitus (197.0 ± 34.0 pmol/mg collagen) and 20 patients without diabetes mellitus (111.9 ± 16.2 pmol/mg collagen). 23 With a power of 80% and an alpha of 5%, each group has to consist of 3 patients. With four groups in our study this would result in at least 12 patients. However, for our secondary objectives, an additional sample size calculation was performed. This calculation was based on skin AGEs in patients with and without diabetes mellitus. This study reported a mean skin AGE level of 2.79 ± 0.8 arbitrary units (AU) in 973 patients with diabetes mellitus and 2.14 ± 0.6 AU in 231 patients without diabetes mellitus. 13 To show a similar difference between patients with and without diabetes mellitus of skin AGEs, 25 patients per group are required. Taking a failure plus dropout rate of 20% into account together with the possibility of subgroup analysis, we should include 30 patients per subgroup, and a total of 120 patients.
Recruitment
The patients will be recruited from the outpatient clinic of vascular surgery located in one of the three following Dutch hospitals: University Medical Center Groningen (UMCG), Martini
Hospital Groningen, and Medisch Spectrum Twente (MST).
Patients will be informed about the study by their treating vascular surgeon.
Detailed written and oral information will be given by the investigator or research coordinator. have an appointment in the vascular laboratory. Blood will be drawn and 24-hour urine will be collected before surgery. Several biopsies will be obtained during surgery, depending on the type of surgery, and of which more details are shown below. Collected tissue biopsies will be stored until analysis.
Study procedures
Blood and urine sampling Blood will be sampled for routine analysis and stored to determine AGEs. For direct analysis blood will be drawn in an EDTA tube, lithium-heparin tube and a sodium fluoride tube. Citrate plasma, EDTA plasma and serum will be stored at -80° Celsius. For the analysis of AGEs, EDTA tubes will be used for blood collection, which will be transported on ice, centrifuged on 4° Celsius and stored at -80° Celsius until batch analysis.
Biopsy
During surgery, full-thickness biopsies from the arterial wall will be taken at pre-defined locations. These biopsies will be marked with sutures to assure cranio-caudal directions. centimeter.
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Storage
After surgery, biopsy material of the arterial tissue will be divided into three equal parts. The first two parts, together with skin, venous and adipose tissue, will be snap frozen and stored at -80° Celsius. The third part, marked with a suture on the most distal part of the biopsy, will be stored in formaldehyde for 24-72 hours. Afterwards, tissue will be dehydrated with ethanol and embedded in paraffin. Materials of MST will be fixed with formaldehyde, stored in 96% ethanol, and transported to the UMCG per batch of 10 samples where these tissues will be embedded in paraffin. Additional biopsy material which will not be used for primary or secondary research questions will be stored for future research. Information about use of additional tissue for future research is included in the patient information and in the informed consent form. Table 2 shows an overview of the outcome measures and measurement methods, which will be described in detail in the following paragraphs.
Outcome measures
Demographics
The patients' characteristics such as date of birth, sex, cardiovascular risk factors, cardiovascular disease, cardiovascular family history, duration of diabetes mellitus, glycemic 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Weight, length, waist and hip diameter will be recorded during visit at the vascular laboratory. Routine blood and urine analysis will be performed to evaluate the presence of diabetes mellitus and to determine several cardiovascular risk factors, including renal function.
AGEs in arterial wall
Analysis of AGEs in the arterial wall, serum and urine will be performed by the laboratory for Metabolism and Vascular Medicine, Maastricht University Medical Center, The Netherlands.
Protein-bound carboxylmethyllysine (CML), Nε-(carboxyethyl)lysine (CEL) and 5-hydro-5-methylimidazolone (MG-H1) will be measured in the first part of the arterial biopsy material with ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS), as described previously. 24 To localize different types of AGEs, 4 millimeter slices will be made from the paraffin embedded arterial tissue. Consecutive slices will be stained with several antibodies, including polyclonal anti-AGE antibody (Abcam, ab23722), monoclonal anti-AGEs antibody for lysine derivates (Biorbyt, orb27490) and monoclonal anti-Pentosidine (Biorbyt, orb27502).
AGEs in fluids
Specific protein-bound plasma and urine AGEs, CML, CEL and MG-H1, will be measured with UPLC-MS/MS, as described previously. 25 Protein-bound plasma and urine pentosidine will be measured using high performance liquid chromatography (HPLC), as described previously. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 AGEs in the skin will be assessed non-invasively with the AGE Reader TM (DiagnOptics Technologies BV, Groningen, The Netherlands). This method uses ultraviolet light to excite specific AGEs. Reflection and emission light are detected and converted into a skin autofluorescence level expressed in arbitrary units. Detailed information about this method is described elsewhere. 27 Both inner forearms will be scanned three times. Patients will be asked not to use sun blockers, skin tanners or skin creams two weeks before the measurement, since these creams influence the skin autofluorescence measurement.
Vascular parameters
Several vascular parameters will be obtained for the ARTERY study. These parameters include blood pressures, toe pressures, and duplex ultrasound of the aorta. In addition, carotid artery intima-media thickness and carotid-femoral pulse wave velocity will be measured in the vascular laboratory of the UMCG only. Measurements will be performed by trained vascular technicians.
Carotid intima-media thickness will be measured as a marker of generalized atherosclerotic burden. The far wall of the left and right common carotid artery will be . Three measurements will be performed with an average of 6 heart beats of the wall segment of 10 millimeters before the transition to the carotid bulb.
Patients are allowed to have a light meal. Arterial waveforms will be obtained from the carotid and femoral artery and the time delay will be measured between the feet of the two waveforms. The distance covered by the waves will be established as 80% of the distance between the two recording sites. Pulse wave velocity will be calculated as distance/time delay in meters/seconds with the use of the Sphygmocor EM3 (AtCor Medical Pty Ltd, West Ryde, Australia).
Data handling and statistical analysis
Described data will be shown as mean with standard deviation for normal distributed variables, mean with interquartile range for skewed data and number with percentages for categorical data. Difference between groups will be tested with the independent student t test or non-parametric tests for skewed data. For categorical variables, Chi-square test will be performed. After comparing differences with a univariate analysis, multivariate analyses will be performed to adjust for important confounders of AGEs. A P<0.05 will be considered significant.
Ethical considerations
Local approval for the ARTERY study was given by the Medical Ethics committee and the 37 We have chosen not to exclude these patients, since patients with vascular disease frequently have renal insufficiency. Exclusion of concurrent renal failure and vascular disease would result in a selection bias. Therefore, we have decided to increase our sample size to allow subgroup analysis. In addition, renal function will be a variable which will be included into multivariate analyses. In addition, biopsy material obtained at the location of disease may not be representative for vascular tissue in general. We standardize the biopsies procedure to minimize location specific differences. However, it is technically and ethically not possible to obtain additional biopsies from different vascular sites to determine whether AGEs are distributed equally.
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